Physician profile
Kelley E Burkett
NPI 1568637882
$810.19
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.30 · 2020: $52.79 · 2021: $79.40 · 2022: $114 · 2023: $186 · 2024: $101 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $266.41 | 2019-2025 | Veozah |
| Abbvie INC. | $139.29 | 2021-2023 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $67.61 | 2020-2024 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Coopersurgical, INC. | $59.93 | 2019-2025 | Endosee |
| Exact Sciences Corporation | $51.15 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $43.27 | 2020-2022 | |
| Daiichi Sankyo INC. | $39.66 | 2021-2025 | Injectafer |
| Biogen, INC. | $26.25 | 2025 | Zurzuvae |
| Baxter Healthcare | $22.50 | 2023 | Tisseel |
| Covidien LP | $20.69 | 2019 | |
| Medtronic Vascular, INC. | $20.36 | 2019 | |
| Novo Nordisk INC | $19.71 | 2023 | Wegovy |
| Aspira Women'S Health INC | $18.37 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Burkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.